Healthcare provider profile · identity verified

An K Phan, MD

Family Practice · SOUTH WEYMOUTH, MA · NPI 1104872274

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	559	183
Lisinopril	Lisinopril	247	75
Levothyroxine Sodium	Levothyroxine Sodium	217	63
Amlodipine Besylate	Amlodipine Besylate	205	72
Losartan Potassium	Losartan Potassium	183	57
Sertraline Hcl	Sertraline Hcl	174	64
Trazodone Hcl	Trazodone Hcl	145	55
Metoprolol Succinate	Metoprolol Succinate	143	54
Hydrochlorothiazide	Hydrochlorothiazide	140	44
Gabapentin	Gabapentin	111	34
Omeprazole	Omeprazole	109	37
Alendronate Sodium	Alendronate Sodium	106	36
Simvastatin	Simvastatin	96	32
Albuterol Sulfate Hfa	Albuterol Sulfate	92	25
Pantoprazole Sodium	Pantoprazole Sodium	92	35
Atenolol	Atenolol	83	25
Rosuvastatin Calcium	Rosuvastatin Calcium	82	29
Famotidine	Famotidine	74	31
Naproxen	Naproxen	73	28
Fluticasone Propionate	Fluticasone Propionate	67	27
Furosemide	Furosemide	62	26
Ozempic	Semaglutide	59	15
Metformin Hcl	Metformin Hcl	55	18
Montelukast Sodium	Montelukast Sodium	51	17
Chlorthalidone	Chlorthalidone	50	17
Metoprolol Tartrate	Metoprolol Tartrate	50	19
Mounjaro	Tirzepatide	46	11
Meclizine Hcl	Meclizine Hcl	44	14
Metformin Hcl Er	Metformin Hcl	43	18
Ezetimibe	Ezetimibe	42	12
Pravastatin Sodium	Pravastatin Sodium	41	14
Fluoxetine Hcl	Fluoxetine Hcl	39	17
Citalopram Hbr	Citalopram Hydrobromide	36	14
Tamsulosin Hcl	Tamsulosin Hcl	36	11
Eliquis	Apixaban	33	suppressed
Synthroid	Levothyroxine Sodium	32	suppressed
Allopurinol	Allopurinol	31	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	28	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	28	suppressed
Mirtazapine	Mirtazapine	28	13
Nystatin	Nystatin	28	20
Finasteride	Finasteride	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	26	15
Buspirone Hcl	Buspirone Hcl	24	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	24	suppressed
Clobetasol Propionate	Clobetasol Propionate	22	12
Hydrocortisone	Hydrocortisone	22	14
Irbesartan	Irbesartan	21	suppressed
Symbicort	Budesonide/Formoterol Fumarate	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Carvedilol	Carvedilol	19	suppressed
Potassium Chloride	Potassium Chloride	19	suppressed
Labetalol Hcl	Labetalol Hcl	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Trulicity	Dulaglutide	18	suppressed
Bumetanide	Bumetanide	17	suppressed
Olanzapine	Olanzapine	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Glipizide	Glipizide	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Tramadol Hcl	Tramadol Hcl	16	suppressed
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Jardiance	Empagliflozin	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Telmisartan	Telmisartan	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Valsartan	Valsartan	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Duloxetine Hcl	Duloxetine Hcl	13	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Prednisone	Prednisone	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error